depression

9511213674_31a3c06cc7_z

Introduction

Clinical, unipolar depression is more than just feeling low for a day or two.

Depression is characterised as episodes of sadness, loss of interest and pleasure, often including feelings of low self-worth. Depression can also include a range of physiological symptoms, such as fatigue, pain, diminished appetite, lack of interest in sex, disturbed sleep, and poor concentration.

The World Health Organisation estimates that, globally, as many as 350 million people are affected at any given time, with one person in 20 reporting an episode of depression in a 12 month period (in a global sample of 17 countries). They describe depression as the leading cause of disability worldwide.

What we know already

We know that, despite the considerable global burden of depression, not everybody receives treatment, with figures ranging from 50% to 10% in less developed countries.

Evidence suggests that combined psychological and pharmacological treatments seem to work well. Broadly, we know that psychotherapies work in many cases – but not every time. We know that neurochemical factors, such as serotonergic dysfunction, play an important role in depression, which goes a long way in explaining the efficacy of SSRI treatments.

We also know that depression has a nasty habit of recurrence, and some psychological interventions, such as Mindfulness-Based Cognitive Therapy (MBCT) is recommended particularly for people who have experienced multiple episodes of depression, but not are currently severely depressed.

We know that people living with chronic physical illness are more likely to experience depression, and this combination is linked with poorer clinical outcomes.

Importantly though, we know that people with depression can still enjoy themselves, and a common misconception in depression is that people feel totally awful all of the time.

Areas of uncertainty

There is much still to determine. For example, we know that depression is hereditable, however the extent of heredity versus environmental influences are unclear.

We are also unsure as to the precise mechanisms that determine those who respond best to treatments, be they psychopharmacological, or psychological, or both.

What’s in the pipeline?

Despite advances in our understanding of depression, and how it is treated, it remains a highly recurrent difficulty, with many people not achieving complete remission between episodes.

Preventative interventions, either physiological, or psychological, may improve people’s resilience to depression, particularly those identified as being highly prone.

References

Cuijpers, P. (2015). Psychotherapies for adult depression: recent developments. Current Opinion in Psychiatry, 28, 24-29. [Abstract]

Naylor, C., Parsonage, M., McDaid, D., Knapp, M., Fossey, M. and Galea, A. (2012) Long-term conditions and mental health: the cost of co-morbidities. The King’s Fund, London, UK [PDF]

World Health Organisation (2015).Factsheet 369: Depression [Link]

Photo Credits

Sascha Kohlmann CC BY 2.0

Acknowledgement

Written by: Patrick Kennedy-Williams
Reviewed by:
Last updated: Nov 2015
Review due: Sep 2016

Our depression Blogs

Systematic review reveals conflicting evidence for relationship between diet and depression

shutterstock_108853694

The question of what role nutrition plays in mental health has been the sauce (ahem) of research interest in recent times. As covered previously by oursElves in relation to dementia, the majority of this research has looked at individual nutrients like Omega-3 fish oil and other minerals, with the broader area of diet receiving less [read the full story…]

It’s not the combat, maybe it’s the drinking in vulnerable young men

shutterstock_82008286

A cohort study published in JAMA tried to answer the question what are the risk factors for suicide in the US military. This is a hot topic as the rate of suicide has increased in US military personnel from about 11/100,000 people in 2005 to about 18/100,000 so that now deaths from suicide outnumber deaths [read the full story…]

Moderators of outcome in late-life depression: should we be prescribing antidepressants to older people?

shutterstock_95774764

Meta-analyses are an incredibly useful tool for synthesising evidence. However, such analyses typically use aggregate data, meaning the average scores or outcomes for treatment groups, which can cause problems if we’re trying to dig a little deeper into the question of ‘what works’ to answer ‘what works, and for whom?’ The ‘for whom?’ question is [read the full story…]

Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: what about the impact of gender?

shutterstock_123610225

Life after cancer diagnosis and treatment is full of uncertainties for the patients and their caregivers. The possibility of cancer returning is hard to dismiss at least in the first few years after the end of treatment. Life has often changed in many imperceptible and subtle ways for people who have undergone cancer treatment, as [read the full story…]

Can brain imaging help predict who will respond to CBT versus antidepressants?

shutterstock_49984888

A major challenge in the treatment of depression is that only a proportion of people respond to the first treatment they try.  For example, with antidepressants only 40% of people will see their symptoms fall to a level that can be considered a recovery.  Trying further treatments after the first one does not work can [read the full story…]

More evidence needed on additional interventions to reduce mortality in older people with depression

Older man

It has consistently been shown that a link exists between older adults who have depression and mortality (Cuijpers & Smit, 2002, Schulz et al., 2002). RCTs have demonstrated that treating depression during later life in primary care settings can result in the remission of depression and its associated symptoms as well as improve quality of [read the full story…]

Lack of evidence to support QOF incentives for assessing depression severity using tools in primary care

Form filling

Introduction The quality and outcomes framework was set up in 2004 to incentivise aspects of clinical practice within general practice in the UK. Two standards which are incentivised in depression are DEP4 (the percentage of patients who have had assessment of severity at diagnosis using a tool validated for use in primary care (PHQ-9, BDI-II, [read the full story…]

Do interventions proven to improve cardiovascular disease outcomes work for individuals with severe mental illness?

shutterstock_high blood pressure

Individuals with severe mental illness (SMI) have shortened life expectancies compared to the general population. This is partly down to higher rates of chronic physical illness. Cardiovascular disease (CVD) is the leading cause of death among patients using mental health services. It is assumed that interventions used to reduce CVD are similarly effective in patients with [read the full story…]

New Cochrane review provides strategies for managing sexual dysfunction brought on by antidepressants

Sexual dysfunction

One of the major complaints of people on antidepressant medication is the effect it has on their sex lives. It does this in three main ways – it affects sexual desire, the ability to achieve and sustain an erection in men and alters the sensation of orgasms and ejaculation. These side effects are one of [read the full story…]

Meta analysis of antidepressants vs talking therapies: another example of ‘All Must Have Prizes’?

Depression

Patients presenting to their GP with a mental health problem are likely to be offered medication, in the form of antidepressants, and/or a ‘talking therapy’, such as counselling or CBT. This is because we know that both those broad categories of treatments (drugs and psychological therapies) are effective in reducing symptoms. However, it’s less clear [read the full story…]